Literature DB >> 12033389

Kinetics and mechanism of hydrolysis of efavirenz.

Michael B Maurin1, Susan M Rowe, Karl Blom, Michael E Pierce.   

Abstract

PURPOSE: To determine the kinetics and mechanism of hydrolysis of efavirenz [(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one] in aqueous solutions.
METHODS: The solution stability was examined at 60 degrees C and an ionic strength of 0.3 M over the pH range of 0.6 to 12.8. The loss of efavirenz and the appearance of degradants were followed with a reverse-phase high-performance liquid chromatography assay. Characterization of the degradants was accomplished with liquid chromatography-mass spectrometry.
RESULTS: The degradation of efavirenz followed apparent first-order kinetics over the pH range of 0.6 to 12.8 at 60 degrees C. The catalytic effect of phosphate and borate buffers was negligible while acetate and citrate demonstrated buffer catalysis. The overall rate constant indicated a pH minimum (the pH of maximum stability) of approximately 4. Mass spectra data identified a degradant with a molecular weight consistent with hydrolysis of the cyclic carbamate to the corresponding amino alcohol. The degradation route was confirmed with spiking experiments with an authentic sample of the amino alcohol indicating that the carbamate hydrolysis pathway was the predominant reaction throughout the pH range studied. Subsequent degradation of the amino alcohol proceeded at the extremes of the pH range studied via rearrangement to the quinoline.
CONCLUSIONS: The pH-rate profile was consistent with a combination of a V-shaped profile in the pH range of 0-9 and a sigmoid-shaped profile in the pH range of 4-13. The plateau that began at pH 10-11 is a result of the ionization of the amine of the carbamate inhibiting the base-catalyzed hydrolysis of efavirenz, given that the ionized form of the carbamate is resonance-stabilized toward hydroxide-catalyzed degradation. Thus, increasing the pH resulted in a parallel decrease in the unionized fraction and increase in hydroxide ion concentration resulting in a constant k(obs) value.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12033389     DOI: 10.1023/a:1015160132290

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  4 in total

Review 1.  HIV inhibitors targeted at the reverse transcriptase.

Authors:  E De Clercq
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

2.  Determination of the pKa and pH-solubility behavior of an ionizable cyclic carbamate, (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- (trifluoromethyl)-2H-3,1-benzoxazin-2-one (DMP 266).

Authors:  S R Rabel; M B Maurin; S M Rowe; M Hussain
Journal:  Pharm Dev Technol       Date:  1996-04       Impact factor: 3.133

3.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

4.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

Authors:  R A Spence; W M Kati; K S Anderson; K A Johnson
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

  4 in total
  8 in total

1.  Study the influence of formulation process parameters on solubility and dissolution enhancement of efavirenz solid solutions prepared by hot-melt extrusion: a QbD methodology.

Authors:  Jaywant Pawar; Dilipkumar Suryawanshi; Kailas Moravkar; Rahul Aware; Vasant Shetty; Mohammed Maniruzzaman; Purnima Amin
Journal:  Drug Deliv Transl Res       Date:  2018-12       Impact factor: 4.617

2.  Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes.

Authors:  Sateeshkumar Sathigari; Gurkishan Chadha; Y-H Phillip Lee; Nydeia Wright; Daniel L Parsons; Vijay K Rangari; Oladiran Fasina; R Jayachandra Babu
Journal:  AAPS PharmSciTech       Date:  2009-01-16       Impact factor: 3.246

3.  Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.

Authors:  Abhijit A Date; Annemarie Shibata; Michael Goede; Bridget Sanford; Krista La Bruzzo; Michel Belshan; Christopher J Destache
Journal:  Antiviral Res       Date:  2012-10-03       Impact factor: 5.970

4.  Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.

Authors:  Abhijit A Date; Annemaria Shibata; Emily McMullen; Krista La Bruzzo; Patrick Bruck; Michael Belshan; You Zhou; Christopher J Destache
Journal:  J Biomed Nanotechnol       Date:  2015-03       Impact factor: 4.099

5.  Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry.

Authors:  Yong Huang; Monica Gandhi; Ruth M Greenblatt; Winnie Gee; Emil T Lin; Nicholas Messenkoff
Journal:  Rapid Commun Mass Spectrom       Date:  2008-11       Impact factor: 2.419

6.  Effect of High-Energy Milling on the Dissolution of Anti-HIV Drug Efavirenz in Different Solvents.

Authors:  Narges Ataollahi; Marica Broseghini; Fabio F Ferreira; Alberto Susana; Massimo Pizzato; Paolo Scardi
Journal:  ACS Omega       Date:  2021-05-03

Review 7.  Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Authors:  Iris Usach; Virginia Melis; José-Esteban Peris
Journal:  J Int AIDS Soc       Date:  2013-09-04       Impact factor: 5.396

8.  Trace Level Quantification of the (-)2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3-butyn-2-ol Genotoxic Impurity in Efavirenz Drug Substance and Drug Product Using LC-MS/MS.

Authors:  Nagadeep Jaishetty; Kamaraj Palanisamy; Arthanareeswari Maruthapillai; Rajamanohar Jaishetty
Journal:  Sci Pharm       Date:  2015-10-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.